HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the fourth quarter and full year, ended Dec. 31, 2022. The company has also scheduled an earnings call and webcast for today at 4:30 p.m. ET to discuss the report. A highlight of the report includes the company’s strategic acquisition of LIVMOR assets, including its FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and physician-prescribed integrated patient care platform, three U.S. patents, business contracts and relationships as well as all Samsung watch and tablet inventory. The report also noted that HeartBeam has partnered with Evolve Manufacturing to build its proprietary AIMIGo 12-Lead 3D vector electrocardiogram device, has been granted a European patent that relates to its flagship technology, and has received a patent for its 12-lead electrocardiogram smartwatch-based monitor; the company also cited key personnel changes during the quarter. Those interested in today’s earnings event can access the call by dialing 1-877-704-4453 in the United States or 1-201-389-0920 internationally, and then using the conference code 13735881. A replay of the call will also be available two hours after the call is concluded. “In our first year as a public company, 2022 was focused on advancing our product launch timeline for the HeartBeam AIMIGo 12-Lead 3D vector electrocardiogram device and HeartBeam AIMI(TM) platform,” said HeartBeam CEO and founder Branislav Vajdic in the press release. “Throughout the fourth quarter and into 2023, our movement toward production and commercialization of our products was underscored by a series of milestones including new acquisitions, partnerships, IP protection and a strengthened management team. We continue to have strong conviction in our HeartBeam AIMI software platform technology and HeartBeam AIMIGo, and their potential to offer more accurate heart attack detection and expedite treatment. As we look toward FDA clearance for HeartBeam AIMI, we are also making significant progress with our core HeartBeam AIMIGo product as we prepare for FDA submission early this year.”
To view the webcast, visit https://ibn.fm/YTEzY
To view the full press release, visit https://ibn.fm/6MFsC
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.